PURPOSE
To review the therapeutic results of the combination of embolization and sclerotherapy, with or without surgery, in patients with peripheral vascular malformations (PVMs).
MATERIALS AND METHODS
A total of 40 patients (24 males and 16 females) with PVMs, who were treated via percutaneous embolization (transarterial [TA] versus direct puncture [DP] ) and sclerotheraphy between March 2003 and September 2009, were included in this retrospective study. The mean age was 28 years (range, 6-66 years), and 9 patients (7 boys, 2 girls) were ≤18 years of age (range, 6-18 years). The 40 patients experienced 40 PVMs, of which 15 were localized to an upper extremity, 13 to a lower extremity, 7 to the axial body, and 5 to the pelvis. A total of 22 PVMs were high-flow, whereas 18 were low-flow. Indications for treatment included pain, swelling, extremity function loss, and cosmetic concerns.
RESULTS
A total of 85 embolization/sclerotheraphy sessions were performed (2.1 sessions per patient). For the 22 high-flow PVMs, 53 treatment sessions were completed (2.4 sessions per lesion). Of the high-flow PVMs, 10 were treated via embolization only (7 DP, 2 TA, 1 DP and TA), 5 via alcohol sclerotheraphy only (2 DP, 2 TA, 1 DP and TA) and 7 via a combination of embolization and sclerotheraphy (3 TA, 4 DP and TA). The agents of embolization and sclerotherapy were n-butyl cyanoacrylate (n=22 patients), Onyx ® (n=12 patients), and alcohol (n=19 patients). A total of 18 low-flow PVMs were treated in 32 sessions (1.8 sessions per lesion), all via the direct puncture approach. Of the low-flow PVMs, 11 were treated with embolization only, 6 with sclerotheraphy only, and 1 with a combined approach. In 16 patients (6 high-flow versus 10 low-flow), after a mean of 2.1 sessions (range, 1-9 sessions), the percutaneously treated lesions were excised by surgery without any major complications. In the 24 patients who did not have surgery, the lesions significantly decreased in size and the complaints from these patients improved. In four patients, skin ulcerations were identified, two of these patients needed surgical grafting; whereas in one patient, sciatic nerve paralysis developed after trans-arterial embolization and recovery was achieved in six months.
CONCLUSION
Percutaneous treatment of PVMs by embolization and sclerotheraphy is a safe and effective method, provided that appropriate lesion classification and treatment agent selection are performed.
the decision to perform sclerotherapy or embolization and the choice of embolic agent was primarily made at this phase of the procedure and depended on the volume of the PVM and how close the tip of the microcatheter could be placed to the actual nidus. Of course, one of the most important factors for choosing the agent used for sclerotherapy/embolization was the presence (or lack) of a surgical plan and the timing of the surgery. After embolization and sclerotherapy procedures, control angiograms were performed. Hemostasis was achieved by manual compression following removal of the catheters, the guidewire and the arterial sheath. In the DP technique for high-flow PVM, a 19-23 G butterfly needle(s) or 21 G micro-puncture needle(s) was placed into the nidus or into the closest arterial or venous site to the PVM and embolization agents (Table 1) were injected under the guidance of fluoroscopy; in the meantime, to guarantee the complete obliteration of the nidus, distal compression was performed when possible. In the DP technique for low-flow PVM, following the appropriate preparation and draping of the puncture site, again a 19-23 G butterfly needle(s) or 21 G micro-puncture needle(s) was placed into the PVM (mostly under ultrasound guidance), diluted contrast was injected into the PVM to depict the vascularity and venous drainage of the PVM and embolization or sclerotherapy agents (Table  1) were injected under the guidance of fluoroscopy. Additional punctures were performed when needed during the DP technique. In both techniques (TA and DP), complete obliteration of the PVM was the goal; for diffuse, large PVMs, additional treatment sessions were performed at 4-6 weeks intervals. Because the dose limitations are important for some agents, such as alcohol and lipiodol, session plans were generally made beforehand, which also affected the surgical plan. Antibiotic prophylaxis and steroid medications were used 3-5 days before and after the treatment sessions in most of the patients, depending on the location and the size of the PVM. Periodic (1-3 months) follow-up evaluations were performed based on the physical examination, using gray scale and/or color Doppler ultrasound and MRI as needed. In the current study, technical success in the embolization and sclerotherapy procedures was defined as a successful catheterization and a subsequent partial or complete obliteration of the PVM lesion via embolization or sclerotherapy; clinical success was defined as an improvement in the initial symptoms of the patient following percutaneous intervention in the non-surgery group and resection of the percutaneously treated PVM without major intraoperative bleeding.
Results
Pre-procedural imaging studies demonstrated 22 high-flow and 18 low-flow PVMs in 40 patients. Classification of the PVMs according to their location and flow pattern is summarized in Table 2 . The 40 PVM in 40 patients were treated with a total of 85 sessions (2.1 sessions per patient). A total of 22 high and 18 low-flow PVM lesions were treated in 53 (2.4 sessions per lesion) and 32 (1.8 sessions per lesion) sessions, respectively. Of the high-flow PVM lesions, 10 were treated with embolization only, five with sclerotherapy only, and seven with combined embolization and sclerotherapy; whereas 11 low-flow PVM lesions were treated with embolization only, six with sclecellular dehydration and ultimately results in endothelial destruction and thrombosis (3). In the current study, all of the embolization and sclerotherapy procedures were performed in an interventional radiology unit under general anesthesia. Transarterial (TA) catheterization and/or direct puncture (DP) techniques were chosen, depending on the flow characteristics of the PVM lesion. The TA catheterization approach was preferred for high-flow PVMs, whereas the DP approach was generally used for low-flow PVMs. However, even in high-flow lesions, DP with or without distal compression was needed in a portion of the cases to completely embolize the nidus itself. For TA embolization in high-flow PVMs, the most proximal main feeding artery of the PVM was first catheterized using a 4 F diagnostic catheter through a 4-5 F arterial sheath placed in the right femoral artery, followed by a selective arteriogram. Then, the distal feeder arteries were super-selectively catheterized with a microcatheter using a co-axial technique. Eventually, the desired embolization or sclerotherapy agents (Table 1) were injected under the guidance of fluoroscopy. Both 
b a
rotherapy only and one with combined embolization and sclerotherapy (Table 3) . A total of seven high-flow PVM lesions were treated using the TA approach, nine with DP and six with a combination of TA and DP; whereas all low-flow PVM lesions were treated with the DP approach ( Table 4 ). All of the percutaneous treatment procedures were successful, and non-targeted embolization or sclerotherapy was not encountered (Figs. 1 and 2 ).
In the follow up, for the 24 patients (16 high-flow, 8 low-flow PVMs) in whom surgical resection was not planned and performed, the PVM lesions diminished in size and the admission complaints improved after a mean of 2.1 percutaneous treatment sessions (range, 1-6 sessions) ( Table  5 ). In sixteen patients (6 high-flow, 10 low-flow), who had a mean percutaneous treatment session number of 2.1 (range, 1-9 sessions), surgical resection was performed in 7 days after completion of the embolization and sclerotherapy session(s), as planned prior to percutaneous treatment, and no major complication (e.g., bleeding) was observed during surgery (Table 5) .
Overall, for the embolization and sclerotherapy procedures, the technical success rate was 100%, whereas the clinical success rate (improvement in any of the initial symptoms: pain, loss of function, cosmetic concern or a successful/ uneventful eventual surgical resection/ curettage) was 100% in both the surgery and the non-surgery groups. As for complications, skin ulceration was observed in four patients who underwent sclerotherapy without subsequent surgical resection, and two of these patients underwent successful surgery for these skin ulcerations, whereas two recovered without any requirement for intervention. One patient, who had combined c embolization and sclerotherapy for a high-flow pelvic PVM, developed sciatic nerve paralysis after the sclerotherapy session, but significant improvement was observed in the paralysis findings in the first six month interval.
Discussion
The management of PVM lesions is challenging due to their complexity and because of the difficultly inherent in selecting the appropriate treatment approach. Surgical excision, which includes excision of the nidus and ligation of the feeding vessels, offers an attractive solution, in theory. However, the infiltrating nature of PVMs, specifically those that are high-flow and large, increases the possibility of recurrence and complications; moreover, a failure during surgical excision can result in the loss of an endovascular treatment attempt. The combination of embolization and sclerotherapy can potentially serve as a treatment method. The utility of percutaneous treatments with various agents, including NBCA, polyvinyl alcohol particles (PVA), Onyx and ethanol, has been reported (6-27). Rockman et al. (6) treated 50 patients with PVMs and used either TA NBCA or DP ethanol to treat high-or low-flow PVMs, respectively; 92% of their patients recovered, whereas 6% needed additional surgical intervention and one patient lost an extremity. Lee et al. (7) reported on 76 patients with PVMs, of whom, 48 (n=16, post embolization/sclerotherapy surgery; n=25, total recovery; n=7, partial recovery) received embolization/sclerotherapy with NBCA, coils and ethanol. In the current study, the embolization and sclerotherapy was technically successful in 100% of the patients. For the majority of the high-flow PVM lesions, the TA approach was the preferred technique, whereas DP was mainly used as an adjunct to ensure complete obliteration of the lesion. Surgical excision was performed in six patients, all of whom had embolization with NBCA and/or Onyx. Symptomatic relief was achieved in all patients who did not undergo surgery and the complication rate for the treatment of high-flow PVM lesions was 22.7% (5/22; n=4 skin ulceration, n=1 transient sciatic nerve paralysis); however, all of the patients recovered from their complications without permanent damage or mortality. For all of the lowflow PVM lesions, the DP approach was preferred and adjunct surgical excision was performed in 10 patients, all of whom had embolization with NBCA, whereas symptomatic relief was achieved in the remaining 8 patients.
No complication or procedure-related mortality was encountered. Our results for the management of PVM lesions and the complication rates were comparable with other studies in the literature (18, 19, 21, 24) .
Currently, there is no consensus on the selection of an appropriate agent for endovascular treatment. The flow pattern of the lesion, the location (deep vs. superficial), operator experience, the presence of an adjunct surgery plan, cost, and availability are the main factors that influence agent selection. The selection of an agent was based on these criteria in the current study. We usually preferred ethanol sclerotherapy or NBCA embolization via the DP route for superficial low-flow PVM lesions, TA embolization with NBCA and/or Onyx was used for deeply located high-flow lesions and NBCA embolization was preferred in patients with an adjunct surgery plan to increase the success rate of excision.
In conclusion, PVM lesions are rare and present challenges in both diagnosis and management. Percutaneous management with embolization and sclerotherapy can be effectively used alone or with surgery for the treatment of PVM lesions, provided that the lesion is correctly classified and an appropriate agent is selected. To achieve better outcomes for these potentially complex lesions, interventional radiologists and plastic surgeons must work together, beginning with the diagnosis and continuing throughout the treatments, so that these lesions can be treated aggressively and patiently, yielding excellent outcomes with an acceptable rate of complications. The choices of the embolization/sclerotherapy route and of the embolic agent play an important role in the management of these lesions and require significant experience and expertise in all kinds of imaging-guided embolization.
